Journal of Clinical & Experimental Dermatology Research
Open Access

Italy

Biography

Dr. Amanda Mazzi belongs to Massimo Milani, Medical Department, Cantabria Labs Difa Cooper, Via Milano 160, Caronno Pertusella (VA), Italy. His research interest includes Autoimmune bullous disease, Epidermolysis, Dermatology, skin, Dermatology.

Publications

• Research Article   
  Efficacy and Tolerability of a Tretinoin 0.02%, Clindamycin 0.8% and Glycolic Acid 4% Gel in Acne: A Multicenter, Prospective, Pragmatic, Assessor-Blinded, 12-Week Trial on 159 Subjects
  Author(s): Massimo Milani*, Chiara Cortelazzi, Paolo Chieco, Anna Ferrazzi, Nicola Gargano, Elisa Maiani, Amanda Mazzi, Maria Grazia Mannino, Daniela Marciani, Sergio Pastena, Silvia Pugliarello, Valentina Salamone, Teresa Sisto, Roberta Scarselli, Carmen Solaroli and Gustavo Span�²
  
  Background: Topical retinoid and antibacterial agents are commonly used as first-line treatments in mild/moderate acne vulgaris (AV). Adherence to retinoid treatment could be limited by the low local tolerability. Literature data show that up to 15% of patients prematurely stop the treatment with retinoids because of skin irritation. A medical device in gel formulation containing tretinoin (0.02%), glycolic acid (4%) and clindamycin (0.8%) is available. So far, no real-life, prospective data regarding efficacy and tolerability of this gel are available. We performed a prospective, multicenter, pragmatic 12-week, assessor-blinded trial. Primary outcomes were the changes of Total acne lesions (TL) count. Secondary outcomes were the evolution of Global Acne Grading System score (GAGS) e and Noninflammatory (NI-L) and Inflammatory (I-L) lesions count. An additional secondary outcome was a.. View More»
  DOI: 10.35248/2155-9554.19.10.503

  Abstract HTML PDF